National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Larotrectinib (Vitrakvi ®) HTA ID: 19050

Larotrectinib (Vitrakvi®) is indicated  for patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion.

NCPE Assessment Process Complete
Rapid review commissioned 20/11/2019
Rapid review completed 13/01/2020
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of larotrectinib compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by the HSE 20/01/2020
Pre-submission consultation with Applicant 20/04/2020
Full submission received from Applicant 11/02/2021
Preliminary review sent to Applicant 16/07/2021
NCPE assessment re-commenced 30/08/2021
Follow-up to preliminary review sent to Applicant 10/09/2021
NCPE assessment re-commenced 15/09/2021
Follow-up II to preliminary review sent to Applicant 05/10/2021
NCPE assessment re-commenced 13/10/2021
Factual accuracy sent to Applicant 22/10/2021
NCPE assessment re-commenced 03/11/2021
NCPE assessment completed 23/11/2021
NCPE assessment outcome The NCPE recommends that larotrectinib (Vitrakvi®) not be recommended for reimbursement, unless cost effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013